Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center


Using Systemic Therapy to Treat HER2+ Breast Cancer

Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.

Kathryn Gold, MD, UC San Diego Health


Dr. Gold on Current Unmet Needs in Squamous Cell Carcinoma of the Lung

Kathryn A. Gold, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses current unmet needs in squamous cell carcinoma of the lung.

Alan J. Tackett, PhD


Molecular Approaches May Increase Responsiveness to Immunotherapy for Patients With Metastatic Melanoma

The recent development of therapeutics which stimulate immune response to tumor cells has revolutionized the treatment landscape for cutaneous melanoma.

Nicholas Stollenwerk, MD


Dr. Stollenwerk on the Effect of Robotic Bronchoscopy on Lung Cancer Diagnosis

Nicholas Stollenwerk, MD, discusses the real-world effects of robotic-assisted bronchoscopy on diagnosis and treatment for patients with lung cancer.

Lori J. Wirth, MD, Massachusetts General Hospital


Future Directions in Biomarker-Based Oncology

Experts in oncology discuss future directions in biomarker-driven therapy.

Shannon L. Maude, MD, PhD


Dr. Maude on Safety of Tisagenlecleucel in Pediatric B-ALL

Shannon L. Maude, MD, PhD, discusses notable long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

Rondell Graham, MBBS


Dr. Graham on the Role of the Pathologist in Biomarker Testing in Breast and GI Cancers

Rondell P. Graham, MBBS, discusses the role of the pathologist in biomarker testing for patients with breast and gastrointestinal cancers.

Sarah Sammons, MD, Duke Cancer Institute


Targeting the PI3K Pathway in HR+/HER2- MBC

The rationale for investigating the role of therapies that target the PI3K pathway in HR+/HER2- metastatic breast cancer.

Russell Langan, MD


RWJBarnabas Health Pioneers Innovative Pancreatic Cyst Surveillance Program

The incidental identification of pancreatic cysts has become more common with the increasing use of imaging modalities in clinical practice.

Mark G. Kris, MD


Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

Hiromichi Shirasu, MD


Dr. Shirasu on the Clinical Implications of ctDNA in CRC

Hiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.

Kevin M. Kalinsky, MD, Columbia University Medical Center


Dr. Kalinsky on Therapeutic Options Beyond Chemotherapy in High-Risk Breast Cancer

Kevin Kalinsky, MD, MS, discusses treatment options beyond chemotherapy in patients with high-risk breast cancer.

Narjust Florez (Duma), MD


Dr. Florez (Duma) on Nihilism in SCLC

Narjust Florez (Duma), MD, discusses nihilism in small cell lung cancer.

Ralph Boccia, MD, Johns Hopkins Medicine


Impact of Trilaciclib on the Treatment Landscape

Ralph Boccia, MD, and Jim Schwartz, RPh, discuss the overall impact the approval for trilaciclib will have on patients’ treatment outcomes, health care expenses, and quality of life.

Afaf E. Osman, MD


Dr. Osman on the SELECT-MDS Trial in Higher-Risk Myelodysplastic Syndrome

Afaf E. Osman, MD, discusses the phase 3 SELECT-MDS trial in patients with higher-risk myelodysplastic syndrome.

Gunsagar Gulati, MD,


Dr. Gulati on the Prevalence of TSC1 and TSC2 Mutations in Solid Tumors

Gunsagar Gulati, MD, discusses the prevalence of TSC1 and TSC2 mutations in solid tumors.

Howard D. Edington, MD


Dr. Edington on the Utilization of TVEC Therapy in Melanoma

Howard D. Edington, MD, discusses the use of talimogene laherparepvec in melanoma.

YunZu Michele Wang, MD


Dr. Wang on the Potential Utility of Ruxolitinib in Pediatric Patients With cGVHD

YunZu Michele Wang, MD, discusses the potential utility of ruxolitinib in children and young adult patients with chronic graft-versus-host disease.

Jill Alldredge, MD


Dr. Alldredge on Managing AEs With PARP Inhibitors in Ovarian Cancer

Jill Alldredge, MD, discusses the toxicities associated with PARP inhibition and the management of those adverse effects in patients with ovarian cancer.

Javier Torres-Roca, MD


Dr. Torres-Roca on Optimizing Radiation Therapy With GARD-Based Dosing in Oncology

Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Carrie Horton, MS, CGC


Horton on Addressing the Equity Gap of Genetic Testing in Cancer Care

Carrie Horton, MS, CGC, discusses the importance of addressing the equity gap of genetic testing in cancer care.

Angel Qin, MD


Dr. Qin on Treatment Considerations for Immunotherapy in NSCLC

Angel Qin, MD, discusses treatment considerations for immunotherapy in patients with newly diagnosed non–small cell lung cancer.

Shari Mycek


Real-World Treatment Reveals Discrepancy Between Actual Care and Clinical Trial Recommendations in MCL

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials.

Kathleen O’Brien


The Desire to Always Do More

Jaffer A. Ajani, MD, has an unyielding drive that has resulted in breakthroughs in a deadly, but often overlooked, disease.

Marlana M. Orloff, MD, Thomas Jefferson University Hospital


Future Management of Uveal Melanoma

The next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.

Gordana Vunjak-Novakovic, PhD, BS, MS


Dr. Vunjak-Novakovic on the Clinical Need for Personalizing Cancer Care

Gordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for personalizing cancer care.

Debra L. Richardson, MD, FACS, FACOG


Dr. Richardson on the Rationale for the UPNEXT Trial in Ovarian Cancer

Debra L. Richardson, MD, FACS, FACOG, discusses the rationale for the ongoing phase 3 UPNEXT trial in platinum-sensitive ovarian cancer.